Levothyroxine: Thyroid medication recalled across US due to low potency

Major Pharmaceuticals has issued an urgent recall for several lots of Levothyroxine Sodium tablets across the United States. This action follows reports of subpotency, meaning the medication may not provide the intended dose of thyroid hormone required for patients with hypothyroidism. The recall, which officially began on July 13, impacts a wide range of dosages, including 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg, and 150 mcg tablets.

These affected products were distributed by both Major Pharmaceuticals and Cardinal Health. Hypothyroidism is a condition where the body does not produce a sufficient amount of thyroid hormone, making the reliability of these replacement tablets critical for patients managing their health. If the medication is less potent than labeled, it may lead to ineffective treatment of the condition.

Patients are advised to check their medication bottles immediately against the lot numbers provided in the official FDA enforcement report. If you possess any of the recalled tablets, stop using them and contact your pharmacist or physician for further instructions on how to secure a replacement. Do not stop your treatment without speaking to your healthcare provider first, as managing thyroid levels requires medical supervision.

This recall is a voluntary measure taken to ensure product safety and quality. The Food and Drug Administration is monitoring the situation to confirm all affected stock is removed from circulation. Please consult your local pharmacy if you have concerns regarding your specific prescription or the origin of your medication supply.